AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pharmaceutical Companies

569.775

-6.316-1.10%

Number of Gainers:7

Number of Losers:14

Number of Flat:24

PE:- -

High:572.746

Open:566.614

Low:561.386

Close:576.090

Volume:56.15M

Turnover:174.49M

Market Cap:78.22B

Float Cap:75.55B

Loading ...

Dimerix's Alignment With US FDA on Phase Three 3 Disease Trial Endpoints, Review Process Suggests Productive Ongoing Dialogue, Euroz Hartleys Says

MT Newswires Live

Buy, hold, sell: BHP, CSL, and Woodside shares

ASX Midday Sector Update: Real Estate Stocks Advance, Health Care Stocks Struggle

MT Newswires Live

BioCina Initiates Comprehensive Manufacturing Program for Patrys' Proprietary Injectable Therapeutic to Alleviate Delirium

Australian shares: A once-in-a-decade chance to build wealth?

How Structural Oversupply In Petroleum Additives At NewMarket (NEU) Has Changed Its Investment Story

Simply Wall St.

Mesoblast Director George Gregory Files Initial Beneficial Ownership Statement

Oncosil Medical Ltd-Results of Entitlement Offer

THOMSON REUTERS

Should I invest $2,000 in the VAS ETF?

Should you buy CSL and Pro Medicus shares today?

Dimerix to Conduct Blinded Review of Phase Three Kidney Disease Trial Data

MT Newswires Live

Racura Oncology Secures Governance Approval For Phase One Trial Testing Its Proprietary Formulation For Non-Small Cell Lung Cancer Treatment

MT Newswires Live

Monday’s HotCopper trends: Elixir, Lynas, Racura, and other daily topics | March 16

The Market Herald

BRIEF-Racura Oncology Receives Governance Approval For Harness-1 Phase 1 Trial Of Rc220

BRIEF-Dimerix To Conduct Review Of Action3 Statistical Assumptions

Actinogen Medical Ltd-CEO Loan-Funded Long-Term Incentive Shares Amendment

THOMSON REUTERS

Here are the latest growth forecasts for the CSL share price

Racura Oncology - Receives Governance Approval for Harness-1 Phase 1 Trial of Rc220

THOMSON REUTERS

Dimerix Ltd - Dimerix to Conduct Review of Action3 Statistical Assumptions

THOMSON REUTERS

These are the 10 most shorted ASX shares

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK7508/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":569.7745,"timestamp":1774587599901,"preClose":576.0902,"halted":0,"volume":56150588,"delay":0,"changeRate":-0.010963,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-6.315735,"latestTime":"03-27 16:00:00 AEDT","open":566.6139,"high":572.7464,"low":561.3856,"amount":174489547,"amplitude":0.01972,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1774825200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1774566000000,1774587600000]],"turnoverRate":0.002157,"increases":7,"decrements":17,"flats":19,"marketCap":78223041730.75,"floatMarketCap":75552955431.4375},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":572.7464,"amplitude":0.01972,"preClose":576.0902,"low":561.3856,"latestPrice":569.7745,"volume":56150588,"delay":0,"open":566.6139,"prevYearClose":644.3692,"prevWeekClose":551.995,"prevMonthClose":592.49,"prevQuarterClose":644.369,"fiveDayClose":551.995,"twentyDayClose":592.49,"sixtyDayClose":644.369,"secType":"PLATE","market":"AU","turnoverRate":0.002157,"marketCap":78223041730.75,"floatMarketCap":75552955431.4375,"timestamp":1774587599901,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":7,"down":14,"flat":24},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620741030","title":"Dimerix's Alignment With US FDA on Phase Three 3 Disease Trial Endpoints, Review Process Suggests Productive Ongoing Dialogue, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2620741030","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620741030?lang=en_us&edition=fundamental","pubTime":"2026-03-17 12:39","pubTimestamp":1773722358,"startTime":"0","endTime":"0","summary":"Dimerix's (ASX:DXB) decision to conduct a blinded review of the Action3 phase 3 study data to confirm statistical assumptions of the primary endpoint after reaching alignment with the US Food and Drug","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4585","BK7508","BK7501","LABU","DXB.AU","BK7067"],"gpt_icon":0},{"id":"2620179884","title":"Buy, hold, sell: BHP, CSL, and Woodside shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620179884","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620179884?lang=en_us&edition=fundamental","pubTime":"2026-03-17 11:58","pubTimestamp":1773719902,"startTime":"0","endTime":"0","summary":"There are a lot of blue-chip ASX 200 shares to pick from on the Australian share market. But not all are necessarily buys right now. So, to narrow things down, let's see what analysts are saying about three of the most popular shares on the ASX 200 index. Here's what you need to know: Image source: Getty Images BHP Group Ltd  BHP is the world's largest mining company and a major producer of commodities such as iron ore, copper, and metallurgical coal. One positive currently working in its favour is the strength in copper prices. Copper is widely viewed as one of the most important commodities for electrification, renewable energy infrastructure, and electric vehicles. With demand expected to rise strongly over the coming decade, BHP's significant exposure to copper could become an increasingly valuable part of its portfolio. But does this make BHP shares a buy?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/17/buy-hold-sell-bhp-csl-and-woodside-shares-2/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/17/buy-hold-sell-bhp-csl-and-woodside-shares-2/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["WDS.AU","BK7507","CSL","SG9999004303.SGD","BK4168","BHP","BHP.AU","BK7511","LU1169589451.USD","BK7142","LU0300736492.USD","LU0300736062.USD","BK4585","BK7095","BK7067","LU1169590202.USD","SGXZ23171101.USD","CSL.AU","BK4588","LU0728928796.USD","BK7501","BK7508","BK4086"],"gpt_icon":0},{"id":"2620419424","title":"ASX Midday Sector Update: Real Estate Stocks Advance, Health Care Stocks Struggle","url":"https://stock-news.laohu8.com/highlight/detail?id=2620419424","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620419424?lang=en_us&edition=fundamental","pubTime":"2026-03-17 09:55","pubTimestamp":1773712554,"startTime":"0","endTime":"0","summary":"Real estate stocks advanced nearly 1% at midday Tuesday.Goodman Group (ASX:GMG) gained more than 1% in recent trade.On the flip side, the health care sector struggled, shedding almost 1%.CSL (ASX:CSL) shares were down nearly 1% in recent trade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4585","XBI","BK7508","XLV","GMG.AU","BK7099","BK7501","BK7511","CSL.AU","BK4581","BK7155","BK7067","BK7510","LABU"],"gpt_icon":0},{"id":"2620415771","title":"BioCina Initiates Comprehensive Manufacturing Program for Patrys' Proprietary Injectable Therapeutic to Alleviate Delirium","url":"https://stock-news.laohu8.com/highlight/detail?id=2620415771","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620415771?lang=en_us&edition=fundamental","pubTime":"2026-03-17 09:05","pubTimestamp":1773709500,"startTime":"0","endTime":"0","summary":"PERTH, Australia, March 17, 2026 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end Contract Development and Manufacturing Organisation  announced it has initiated a comprehensive CMC program for the advancement of RLS-2201, a proprietary injectable formulation of Quetiapine being developed by Patrys Ltd  for the acute treatment of delirium in intensive care settings.Sterile injectable manufacturing using a closed isolator system, BioCina Perth. A reformulated RLS-2201 is being produced at BioCina's sterile manufacturing facility in Perth, under conditions designed to confirm the reproducibility and robustness of the manufacturing process. The reformulated RLS-2201 will support ICH-aligned stability studies required for regulatory submission and provide early supply for Patrys' planned first-in-human clinical activities.\"We are proud to be advancing RLS-2201 alongside a world-class CDMO partner whose deep manufacturing expertise and technical capabilities are proving instrumental in","market":"other","thumbnail":"https://mma.prnewswire.com/media/2933870/patrys_release_image_250225_8335.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2933870/patrys_release_image_250225_8335.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/biocina-initiates-comprehensive-manufacturing-program-for-patrys-proprietary-injectable-therapeutic-to-alleviate-delirium-302715013.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CDMO","BK7508","PAB.AU","BK4139"],"gpt_icon":0},{"id":"2620497799","title":"Australian shares: A once-in-a-decade chance to build wealth?","url":"https://stock-news.laohu8.com/highlight/detail?id=2620497799","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620497799?lang=en_us&edition=fundamental","pubTime":"2026-03-17 06:30","pubTimestamp":1773700200,"startTime":"0","endTime":"0","summary":"At first glance, the Australian share market doesn't look particularly cheap.  Even after the recent pullback driven by escalating tensions in the Middle East, the S&P/ASX 200 Index (ASX: XJO) is stil","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/17/australian-shares-a-once-in-a-decade-chance-to-build-wealth/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/17/australian-shares-a-once-in-a-decade-chance-to-build-wealth/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["XJO.AU","BK7049","BK7511","TWE.AU","BK7070","BK7503","PME.AU","BK7067","TLX.AU","XRO.AU","CSL.AU","ALL.AU","BK7007","AMC.AU","TPW.AU","XKO.AU","BK7501","BK7508","WTC.AU","BK7063","BK7103","BK7044","SIG.AU","BK7078","BK7016","XAO.AU","FLT.AU","BK7107","COH.AU","BK7097","BK7505","JHX.AU","BK7094"],"gpt_icon":0},{"id":"2620901504","title":"How Structural Oversupply In Petroleum Additives At NewMarket (NEU) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2620901504","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620901504?lang=en_us&edition=fundamental","pubTime":"2026-03-17 06:20","pubTimestamp":1773699630,"startTime":"0","endTime":"0","summary":"Recently, NewMarket Corporation has come under pressure as its core petroleum additives business faces structural oversupply, with global capacity additions outstripping demand and intensifying competition from Chinese exporters.\nAn additional concern for investors is that bearish research has highlighted how NewMarket’s heavy reliance on this challenged segment could weigh on overall profitability despite past diversification efforts.\nAgainst this backdrop, we’ll explore how persistent...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/2024000-choice2-main-header/1585186739035","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2024000-choice2-main-header/1585186739035"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/materials/nyse-neu/newmarket/news/how-structural-oversupply-in-petroleum-additives-at-newmarke","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/materials/nyse-neu/newmarket/news/how-structural-oversupply-in-petroleum-additives-at-newmarke","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NEU","BK4109","NEU.AU","BK7096","BK7508"],"gpt_icon":0},{"id":"2620497684","title":"Mesoblast Director George Gregory Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620497684","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620497684?lang=en_us&edition=fundamental","pubTime":"2026-03-17 06:07","pubTimestamp":1773698829,"startTime":"0","endTime":"0","summary":"Mesoblast reported an initial statement of beneficial ownership by director George Gregory. The filing listed indirect warrants for 6.83 million ordinary shares with an exercise price of USD 2.86. It also listed direct warrants for 200,000 ADS with an exercise price of USD 9.06. The filing also included direct options covering 66,667 ordinary shares with an exercise price of USD 1.72.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mesoblast Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 16, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL8ctFfz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MSB.AU","BK7508","BK7501","BK7067"],"gpt_icon":0},{"id":"2620492036","title":"Oncosil Medical Ltd-Results of Entitlement Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2620492036","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620492036?lang=en_us&edition=fundamental","pubTime":"2026-03-17 05:51","pubTimestamp":1773697884,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUEBVP5MC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","OSL.AU","BK7048"],"gpt_icon":0},{"id":"2620948434","title":"Should I invest $2,000 in the VAS ETF?","url":"https://stock-news.laohu8.com/highlight/detail?id=2620948434","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620948434?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:44","pubTimestamp":1773693863,"startTime":"0","endTime":"0","summary":"Exchange-traded funds  have become one of the simplest and most popular ways to invest in the share market. It's clear to see why this is the case. Instead of picking individual shares, investors can buy a single ETF and gain exposure to dozens or even hundreds of businesses at once. For investors looking for broad exposure to Australian shares, one of the most favoured options is the Vanguard Australian Shares Index ETF . So if I had $2,000 ready to invest, would I consider putting it into this ETF?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/17/should-i-invest-2000-in-the-vas-etf/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/17/should-i-invest-2000-in-the-vas-etf/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["CBA.AU","BK4550","BK7501","XAO.AU","BHP.AU","BK7016","BK7511","BK7503","TNE.AU","CSL.AU","BK7067","BK7507","BK4585","BK4588","VAS.AU","XJO.AU","XKO.AU","LOV.AU","BK7508","NWL.AU","BK7135","BK7128","BK7062","FDN","NAB.AU","BK7095"],"gpt_icon":0},{"id":"2620951954","title":"Should you buy CSL and Pro Medicus shares today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2620951954","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620951954?lang=en_us&edition=fundamental","pubTime":"2026-03-17 03:00","pubTimestamp":1773687600,"startTime":"0","endTime":"0","summary":"Healthcare shares have been among the biggest fallers on the ASX over the past year. Two of the sector's biggest names — CSL Ltd  and Pro Medicus Ltd  — have both seen their share prices slump heavily. They declined roughly 40% or more over the past 12 months. When CSL and Pro Medicus shares fall this far, investors often start asking the same question: is this a buying opportunity, or a sign that more downside is ahead?","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/17/should-you-buy-csl-and-pro-medicus-shares-today/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/17/should-you-buy-csl-and-pro-medicus-shares-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["SGXZ23171101.USD","LU0728928796.USD","BK7511","BK7067","BK4086","CSL","LU1169590202.USD","BK7508","LU1169589451.USD","BK7501","CSL.AU","PME.AU","BK7094","SG9999004303.SGD"],"gpt_icon":0},{"id":"2619805884","title":"Dimerix to Conduct Blinded Review of Phase Three Kidney Disease Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2619805884","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619805884?lang=en_us&edition=fundamental","pubTime":"2026-03-16 10:14","pubTimestamp":1773627284,"startTime":"0","endTime":"0","summary":"Dimerix  is set to conduct a blinded review of the ACTION3 phase three study data to confirm statistical assumptions of the primary endpoint during March, according to a Monday Australian bourse filing.It will use methods specified in the study's statistical analysis plan previously submitted to the US Food and Drug Administration .The phase 3 Action3 trial is a placebo-controlled study of the efficacy and safety of its DMX-200 drug candidate in patients with focal segmental glomerulosclerosis who are receiving a stable dose of a blood pressure medication known as an angiotensin II receptor blocker. It is designed to capture evidence of proteinuria reduction and kidney function during the trial, aimed at generating sufficient evidence to support marketing approval.The FDA previously confirmed that the proposed primary endpoint of percent reduction in proteinuria compared to placebo is suitable to support traditional approval of DMX-200 via the 505 pathway, with estimated glomerular fil","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","DXB.AU","BK7501"],"gpt_icon":0},{"id":"2619190482","title":"Racura Oncology Secures Governance Approval For Phase One Trial Testing Its Proprietary Formulation For Non-Small Cell Lung Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2619190482","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619190482?lang=en_us&edition=fundamental","pubTime":"2026-03-16 09:23","pubTimestamp":1773624182,"startTime":"0","endTime":"0","summary":"Racura Oncology  received governance approval from Monash Health for its phase one clinical trial assessing the safety, tolerability, and pharmacokinetics of RC220, its proprietary formulation of bisantrene, in combination with osimertinib, in patients with non-small cell lung cancer who have activating epidermal growth factor receptor mutations, according to a Monday Australian bourse filing.Osimertinib is the current standard of care treatment for non-small cell lung cancer with defined epidermal growth factor receptor mutations, the company said in an earlier filing.Teams from Racura Oncology, Monash Health, and Contract Research Organisation Beyond Drug Development will meet at Monash Medical Centre in Clayton, Victoria, for site initiation and training on March 23. This will allow the first patients to be recruited into the trial.The secondary and exploratory endpoints include progression-free survival, overall survival, changes in levels of circulating tumor DNA, and changes in t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RAC.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2619827334","title":"Monday’s HotCopper trends: Elixir, Lynas, Racura, and other daily topics | March 16","url":"https://stock-news.laohu8.com/highlight/detail?id=2619827334","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619827334?lang=en_us&edition=fundamental","pubTime":"2026-03-16 09:14","pubTimestamp":1773623640,"startTime":"0","endTime":"0","summary":"Energy, materials, and health care are all getting a run at the top of the HotCopper forums, with each of the top three managing to stay above what was a pretty red open Monday .Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.First up, Elixir Energy  has got chins wagging by landing an “exceptional” outcome in the final drilling results of the Lorelle-3H appraisal well within Queensland’s Taroom Trough. The well hit 1,033m of high-quality net gas-condensate pay within the targeted Tinowon ‘Dunk’ sandstone, which is now being described as one of the highest impact wells to be drilled in the trough this year.Racura Oncology  brought up the rear in the top three on HotCopper today. The ever-popular healthcare company received governance approval from Monash Health for the HARNESS-1 Phase 1 trial of RC220 in EGFR non-small cell lung cancer patients being treated with osimertinib.And loo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"markerherald_stock","url":"https://themarketonline.com.au/mondays-hotcopper-trends-elixir-lynas-racura-and-other-daily-topics-march-16-2026-03-16/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/mondays-hotcopper-trends-elixir-lynas-racura-and-other-daily-topics-march-16-2026-03-16/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["EXR.AU","BK7507","RAC.AU","BK7142","BK7095","BK7508","LYC.AU","BK7067"],"gpt_icon":0},{"id":"2619484771","title":"BRIEF-Racura Oncology Receives Governance Approval For Harness-1 Phase 1 Trial Of Rc220","url":"https://stock-news.laohu8.com/highlight/detail?id=2619484771","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619484771?lang=en_us&edition=fundamental","pubTime":"2026-03-16 09:08","pubTimestamp":1773623280,"startTime":"0","endTime":"0","summary":"BRIEF-Racura Oncology Receives Governance Approval For Harness-1 Phase 1 Trial Of Rc220March 16 (Reuters) - Racura Oncology Ltd RAC.AX:RECEIVES GOVERNANCE APPROVAL FOR HARNESS-1 PHASE 1 TRIAL OF RC220Further company coverage: RAC.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nFWN40200N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","RAC.AU"],"gpt_icon":0},{"id":"2619484775","title":"BRIEF-Dimerix To Conduct Review Of Action3 Statistical Assumptions","url":"https://stock-news.laohu8.com/highlight/detail?id=2619484775","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619484775?lang=en_us&edition=fundamental","pubTime":"2026-03-16 09:07","pubTimestamp":1773623244,"startTime":"0","endTime":"0","summary":"BRIEF-Dimerix To Conduct Review Of Action3 Statistical AssumptionsMarch 16 (Reuters) - Dimerix Ltd DXB.AX:DIMERIX TO CONDUCT REVIEW OF ACTION3 STATISTICAL ASSUMPTIONSFurther company coverage: DXB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nFWN4011FE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","DXB.AU","BK7508","BK7067"],"gpt_icon":0},{"id":"2619857154","title":"Actinogen Medical Ltd-CEO Loan-Funded Long-Term Incentive Shares Amendment","url":"https://stock-news.laohu8.com/highlight/detail?id=2619857154","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619857154?lang=en_us&edition=fundamental","pubTime":"2026-03-16 06:04","pubTimestamp":1773612284,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260315:nTUE5QQMV7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ACW.AU","BK7067","BK7508"],"gpt_icon":0},{"id":"2619485792","title":"Here are the latest growth forecasts for the CSL share price","url":"https://stock-news.laohu8.com/highlight/detail?id=2619485792","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619485792?lang=en_us&edition=fundamental","pubTime":"2026-03-16 06:00","pubTimestamp":1773612000,"startTime":"0","endTime":"0","summary":"The CSL Ltd (ASX: CSL) share price has been through a tough time over the past two years. As the chart below shows, it's down more than 50% since August 2024.  As a result of this decline, it has fall","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/16/here-are-the-latest-growth-forecasts-for-the-csl-share-price-4/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/16/here-are-the-latest-growth-forecasts-for-the-csl-share-price-4/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["SGXZ23171101.USD","BK7501","IE0034235071.USD","LU1863844749.USD","BK4588","BK4086","BK7067","LU1169589451.USD","BK7041","LU1169590202.USD","BK7153","MQG.AU","BK4118","BK7508","BK4534","BK7046","WES.AU","BK4585","LU0728928796.USD","SG9999004303.SGD","LU3187612489.SGD","LU1829250122.USD","CSL","CSL.AU","LU1863844665.USD","UBS","BK7511"],"gpt_icon":0},{"id":"2619485234","title":"Racura Oncology  - Receives Governance Approval for Harness-1 Phase 1 Trial of Rc220","url":"https://stock-news.laohu8.com/highlight/detail?id=2619485234","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619485234?lang=en_us&edition=fundamental","pubTime":"2026-03-16 05:56","pubTimestamp":1773611808,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260315:nFWN40200N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","RAC.AU"],"gpt_icon":0},{"id":"2619485692","title":"Dimerix Ltd - Dimerix to Conduct Review of Action3 Statistical Assumptions","url":"https://stock-news.laohu8.com/highlight/detail?id=2619485692","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619485692?lang=en_us&edition=fundamental","pubTime":"2026-03-16 05:29","pubTimestamp":1773610167,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260315:nFWN4011FE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","DXB.AU","BK7501"],"gpt_icon":0},{"id":"2619485889","title":"These are the 10 most shorted ASX shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2619485889","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619485889?lang=en_us&edition=fundamental","pubTime":"2026-03-16 05:01","pubTimestamp":1773608499,"startTime":"0","endTime":"0","summary":"At the start of each week, I like to look atASIC's short position reportto find out which shares are being targeted by short sellers.This is because I believe it is well worth keeping a close eye on short interest levels as high levels can sometimes be a sign that something isn't quite right with a company.With that in mind, here are the 10 most shorted shares on the ASX this week according to ASIC:. Domino's Pizza Enterprises Ltd  is the most shorted ASX share with short interest of 15.6%. It appears that short sellers believe the struggling pizza chain operator's turnaround strategy will not be a success.Treasury Wine Estates Ltd  has seen its short interest rise to 14.8%. This wine giant has been battling very tough trading conditions. Short sellers may not believe a change is coming in the near term.Polynovo Ltd  has short interest of 13%, which is up since last week. This medical device company's shares trade on sky-high earnings multiples.Flight Centre Travel Group Ltd  has short","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/16/these-are-the-10-most-shorted-asx-shares-16-march-2026/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/16/these-are-the-10-most-shorted-asx-shares-16-march-2026/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7132","IEL.AU","BK7507","DMP.AU","BK7097","BK7095","GYG.AU","BK7067","FLT.AU","BK7137","BK7126","BK7070","BOE.AU","BK7083","NAN.AU","TWE.AU","BK7505","LYC.AU","BK7508","TLX.AU","PNV.AU","BK7503"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":5,"totalSize":126,"code":"91000000","status":"200"}]}}